Array BioPharma: ARRY-797 Trial Data Shows Promising Clinical Activity

(RTTNews) - Array BioPharma (ARRY) reported results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis. The results demonstrated an absolute mean change from baseline of 69 meters on the six-minute walk test at week 12, the study's primary endpoint.

The company has met with regulators to discuss the design of a study that could be the basis for marketing approval. Array is evaluating different options to advance the ARRY-797 program, including advancing it on its own, partnering the program for further development and commercialization or creating a separate company based on this asset.